Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Abeona Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ABEO
Nasdaq
8731
https://abeonatherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Abeona Therapeutics Inc
Aerie (AERI) Starts Late-Stage Study to Treat Dry Eye Disease
- May 25th, 2022 6:29 pm
Athersys (ATHX) Down as Ischemic Stroke Study Fails to Meet Goal
- May 23rd, 2022 7:32 pm
Enanta's (ENTA) RSV Drug Fails to Meet Study Goal, Stock Drops
- May 19th, 2022 7:02 pm
Abeona Therapeutics Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule
- May 19th, 2022 11:30 am
AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study
- May 18th, 2022 7:12 pm
Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate
- May 18th, 2022 3:47 pm
AbbVie (ABBV) Buys Option Rights to NextGen Inflammation Drug
- May 17th, 2022 1:27 pm
Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics
- May 17th, 2022 12:00 pm
Abeona Therapeutics Reports First Quarter 2022 Financial Results
- May 13th, 2022 11:30 am
AbbVie's (ABBV) Rinvoq Meets Crohn's Disease Study Goals
- May 12th, 2022 6:47 pm
Epizyme (EPZM) Q1 Earnings Miss, Revenues Lag Estimates
- May 11th, 2022 6:28 pm
Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Top Estimates
- May 10th, 2022 6:36 pm
Bausch (BHC) Q1 Earnings and Revenues Miss, Stock Down
- May 10th, 2022 3:37 pm
Aerie (AERI) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
- May 6th, 2022 7:48 pm
ChemoCentryx (CCXI) Q1 Earnings and Sales Miss Estimates
- May 6th, 2022 7:38 pm
Abeona Therapeutics Announces AAV204, a Novel AAV Capsid, Demonstrated Robust Macular Transduction Following Para-Retinal Administration in Non-Human Primates
- May 4th, 2022 11:30 am
Dianthus, a new $100M startup, aims to make autoimmune treatments easier
- May 3rd, 2022 11:00 am
Abeona Therapeutics Announces Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
- Apr 29th, 2022 1:00 pm
Abeona Therapeutics Announces Pricing of $25 Million Private Placement of Convertible Redeemable Preferred Stock
- Apr 29th, 2022 11:30 am
Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth?
- Apr 19th, 2022 2:51 pm
Scroll